Nevertheless, prostate cancer has been one of the most widely investigated solid tumor types for CAR-T therapies, as clinical-stage cell products have most often targeted prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA). This evidence concerns the gene FOLH1 and prostate cancer.